Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Myra Bridges
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: LAM40124 Title: An Assessment of Behavioral Changes Associated with and in Patients with Epilepsy Rationale: Mood symptoms and associated behavioral changes can have a significant impact on the quality of life and functional ability of patients with epilepsy. The etiology of mood symptoms and associated behavioral changes in epilepsy has been attributed to several causes including endocrine and/or metabolic effects of seizures; the psychological response to epilepsy and its mental, physical, and social challenges; and side effects of certain antiepileptic drugs. Previous observations suggest that lamotrigine has a better tolerability profile than levetiracetam with respect to effects on mood. However, the medications have not been directly compared in a study prospectively designed to assess mood and related behavioral effects. This randomized, double-blind clinical trial was designed to compare the effects of adjunctive lamotrigine with those of adjunctive levetiracetam on mood, particularly anger and hostility, in subjects with partial seizures. Phase: IV Study Period: 15 September 2003 to 08 September 2006 Study Design: Randomized, double-blind, parallel-group, multicenter study Centres: 62 centers in North America Indication: Epilepsy Treatment: Subjects were titrated from an initial daily dose of 50mg of lamotrigine to a target maintenance dose of 400 mg/day or from an initial daily dose of 500mg levetiracetam to a target dose of 2000 mg/day over a period of 8 weeks during the Escalation Phase. Subjects were maintained at the target dose for 12 weeks during the Maintenance Phase. Dose adjustments were allowed during the Maintenance Phase to maintain seizure control or reduce adverse events. Objectives: Primary: To compare the occurrence of anger and hostility in subjects with partial seizures treated with lamotrigine or levetiracetam as adjunctive therapy Secondary: To compare the safety and tolerability of lamotrigine and levetiracetam as adjunctive therapy in subjects with partial seizures Primary Outcome/Efficacy Variable: Change in the Anger-Hostility subscale score of the Profile of Mood States (POMS) between and the end of the Maintenance Phase Secondary Outcome/Efficacy Variables: Change between and each weekly assessment in the Anger-Hostility subscale score of the POMS Change between and each weekly assessment in the Total Mood Disturbance score and the other subscale scores of the POMS Change between and the end of the Maintenance Phase in scores on the State Trait Anger Expression Inventory (STAXI), the Beck Depression Inventory, 2 nd edition (BDI-II), the Irritability-Depression-Anxiety Scale (IDAS), and the 31-item Quality of Life Inventory in Epilepsy (QOLIE-31) Change between and the ends of the Escalation Phase and the Maintenance Phase in scores on the Neurological Disorders Depression Inventory in Epilepsy (NDDI-E) and the Epworth Sleepiness Scale (ESS) Change between and the ends of the Escalation Phase and the Maintenance Phase in scores on the NDDI-E completed by a family member or friend The frequency and severity of antiepileptic drug-associated adverse events as scored by the Adverse Events Profile (AEP) at the ends of the Escalation Phase and the Maintenance Phase The investigator-rated assessment of mood and overall response to therapy scored on the Clinical Global Impression Scale (CGI) at the ends of the Escalation phase and the Maintenance Phase The frequency of seizures after treatment with lamotrigine or levetiracetam as adjunctive therapy The incidence of treatment-emergent adverse events The proportion of subjects who prematurely withdrew from the study and the reason(s) for premature withdrawal Statistical Methods: All data were analyzed for the Intent-to-Treat Population, defined as all enrolled subjects who took at least one dose of study medication. Differences between treatment groups on the primary endpoint were compared with nonparametric analysis of covariance (ANCOVA) methods. Differences between groups on the secondary health outcomes measures including the STAXI, BDI-II, IDAS, QOLIE-31, NDDI-E, ESS, and AEP were compared with parametric ANCOVA methods. CGI scores at the end of the Escalation Phase and the Maintenance Phase were compared between treatment groups with a chi-square test. Two-way ANOVAs based on ranks with 1
2 treatment group as a predictor variable were used to compare treatment groups with respect to seizure counts per month and absolute and percent changes from in seizure frequency during the Escalation Phase, the Maintenance Phase, and both phases combined. The percentage of subjects with 25%, 50%, and 75% reductions in seizure frequency and the percentage of subjects seizure free during the Escalation Phase, the Maintenance Phase, and both phases combined were compared between treatment groups with Fisher s Exact test. Adverse events reported during the study were summarized with descriptive statistics. Vital signs, results of clinical laboratory tests, and serum trough concentrations of study medication at the ends of the Escalation and Maintenance Phases were summarized for each treatment group with descriptive statistics. Study Population: The study enrolled men or women at least 16 years old who had a confident diagnosis of epilepsy with at least 2 simple partial seizures or complex partial seizures with or without secondary generalization during the 6 months before study entry and who at study entry were receiving monotherapy with a stable dose of carbamazepine or phenytoin or polytherapy that included carbamazepine or phenytoin and one other antiepileptic drug. Number of Subjects: Planned, N Randomised, N Completed, n (%) 89 (67) 89 (65) Total Number Subjects Withdrawn, N (%) 43 (33) 47 (35) Withdrawn due to Adverse Events n (%) 14 (11) 24 (18) Withdrawn due to Lack of Efficacy n (%) 0 (0) 0 (0) Withdrawn for other reasons n (%) 29 (22) 23 (17) Demographics N (ITT) Females: Males 63:69 56:80 Mean Age, years (SD) 38.3 (12.3) 39.1 (11.6) Race, n (%) Asian Black Hispanic White Other 0 (0) 22 (17) 11 (8) 94 (71) 5 (4) Primary Efficacy Results: Results for the Anger-Hostility Subscale of the POMS (Primary Endpoint) N= p value score (9.0) (8.7) NA Change from to the end of the Maintenance Phase (LOCF) (8.2) (8.4) Secondary Outcome Variables: Anger-Hostility Scale on POMS: Change from (LOCF) N= (9.0) (8.7) Week (6.5) (6.2) Week (7.0) (7.5) Week (8.0) (7.8) Week (8.1) (7.4) Week (8.0) (8.3) Week (8.7) (8.6) Week (9.1) (8.9) Week (8.1) (7.4) Week (8.5) (7.5) Week (8.0) (7.8) Week (8.2) (7.9) Week (8.5) (7.8) 2 (1) 23 (17) 11 (8) 99 (73) 1 (<1) 2
3 Week (8.4) (7.5) Week (8.5) (8.1) Week (8.4) (8.3) Week (8.4) (8.4) Week (8.8) (8.9) Week (8.8) (8.4) Week (8.7) (8.6) Week (8.2) (8.4) Total Mood Disturbance Score on POMS: Change from (LOCF) N= (39.8) (38.0) Week (24.7) (23.8) Week (29.1) (27.5) Week (30.4) (30.9) Week (31.9) (28.9) Week (32.1) (31.9) Week (33.1) (33.1) Week (35.5) (33.3) Week (31.8) (31.0) Week (32.7) (30.5) Week (33.5) (32.3) Week (34.2) (32.4) Week (34.4) (32.3) Week (36.1) (31.2) Week (36.5) (33.1) Week (35.3) (35.0) Week (35.7) (34.0) Week (36.9) (35.3) Week (36.8) (33.8) Week (37.4) (34.5) Week (33.9) (34.3) Tension-Anxiety Scale on POMS: Change from (LOCF) N= (7.6) (7.3) Week (5.2) (5.5) Week (6.0) (5.0) Week (6.3) (6.2) Week (6.9) (5.7) Week (6.7) (6.5) Week (6.7) (6.1) Week (7.3) (6.1) Week (7.0) (5.8) Week (7.1) (6.1) Week (7.4) (6.5) Week (6.9) (6.3) Week (7.5) (6.5) Week (7.2) (6.3) Week (7.2) (6.5) Week (7.1) (6.8) Week (7.1) (6.8) Week (7.3) (6.9) Week (7.2) (6.8) Week (7.5) (6.3) Week (7.3) (6.7) Depression-Dejection Scale on POMS: Change from (LOCF) N= 3
4 (11.3) (11.5) Week (7.3) (7.2) Week (9.3) (8.8) Week (8.8) (9.7) Week (9.2) (9.8) Week (9.5) (10.6) Week (10.1) (11.1) Week (10.5) (10.7) Week (8.9) (10.6) Week (9.1) (10.3) Week (9.4) (10.5) Week (10.1) (10.4) Week (10.2) (10.6) Week (10.7) (10.2) Week (10.8) (11.1) Week (10.3) (11.2) Week (10.6) (11.2) Week (10.8) (11.4) Week (10.7) (10.9) Week (10.9) (11.4) Week (9.9) (11.4) Vigor-Activity Scale on POMS: Change from (LOCF) N= (6.7) (6.5) Week (4.8) (5.1) Week (5.6) (5.8) Week (4.9) (5.7) Week (5.4) (5.9) Week (5.6) (5.8) Week (5.9) (5.7) Week (5.8) (6.3) Week (5.9) (6.2) Week (5.7) (6.4) Week (6.1) (6.6) Week (6.3) (6.2) Week (6.1) (5.8) Week (6.0) (5.8) Week (6.3) (6.0) Week (6.1) (6.6) Week (6.0) (6.2) Week (6.2) (6.0) Week (6.1) (6.2) Week (6.3) (6.5) Week (6.0) (5.7) Fatigue-Inertia Scale on POMS: Change from (LOCF) N= (6.6) (6.4) Week (5.6) (5.3) Week (6.0) (5.6) Week (6.4) (6.1) Week (6.5) (5.6) Week (6.6) (6.3) Week (6.6) (6.2) Week (7.2) (6.2) Week (6.4) (5.8) Week (6.8) (5.7) 4
5 Week (6.8) (5.7) Week (6.9) (6.0) Week (6.7) (6.0) Week (7.1) (6.2) Week (7.1) (6.3) Week (7.3) (6.8) Week (7.4) (6.2) Week (7.4) (6.7) Week (7.5) (6.3) Week (7.5) (6.3) Week (7.1) (6.1) Confusion-Bewilderment Scale on POMS: Change from (LOCF) N= (5.5) (5.4) Week (3.5) (4.1) Week (3.8) (4.4) Week (3.9) (4.5) Week (4.1) (4.0) Week (4.3) (4.6) Week (4.6) (4.9) Week (4.7) (5.2) Week (4.5) (4.6) Week (4.8) (4.6) Week (4.9) (4.9) Week (5.0) (4.9) Week (4.7) (4.9) Week (4.9) (4.8) Week (4.9) (5.0) Week (4.7) (5.1) Week (4.9) (5.1) Week (5.0) (5.2) Week (4.9) (5.3) Week (5.1) (5.2) Week (4.9) (4.9) STAXI: Change from Feeling Angry Feeling Expressing Anger Verbally Feeling Expressing Anger Physically Angry Temperament Angry Reaction Anger Expression-Out Anger Expression-In Anger Control-Out N= 6.6 (3.0) 0.4 (3.7) 6.2 (2.8) 0.2 (3.4) 5.6 (2.2) 0.3 (2.7) 6.7 (3.0) -0.1 (2.3) 7.6 (2.6) -0.4 (2.6) 15.8 (4.8) -0.4 (3.9) 16.4 (4.7) -0.9 (4.2) 6.2 (5.0) 0.7 (2.5) 5.7 (2.0) 0.4 (2.1) 5.4 (1.4) 0.0 (1.6) 6.2 (2.5) 0.0 (2.1) 7.3 (2.4) 0.0 (2.2) 14.7 (4.0) -0.3 (3.4) 16.3 (4.0) -0.1 (3.7) 5
6 Anger Control-In State Anger Scale Trait Anger Scale Anger Expression Index Total BDI-II: Change from IDAS: Change from Irritability Depression Anxiety QOLIE-31: Change from Seizure Worry Overall Quality of Life Emotional Well-Being Energy/Fatigue Cognitive Functioning Medication Effects Social Functioning Overall Score 23.2 (5.8) -0.5 (5.2) 22.3 (5.7) 0.0 (5.7) 18.3 (7.3) 0.8 (8.9) 17.5 (5.8) -0.6 (5.0) 34.9 (16.0) -0.8 (13.9) 23.9 (5.4) -1.0 (4.6) 23.2 (5.3) -0.7 (4.9) 17.3 (5.4) 1.1 (5.3) 16.6 (5.1) 0.1 (4.0) 31.7 (13.9) 1.2 (11.2) N= (10.6) 12.2 (10.6) (7.7) -0.7 (6.6) N= 4.1 (2.9) -0.3 (2. 2) 4.9 (3.1) -0.3 (2.6) 5.3 (3.2) -0.5 (3.0) 3.5 (2.4) 0.6 (2.1) 4.6 (2.9) 0.4 (2.0) 4.7 (3.0) 0.1 (2.3) N= NDDI-E completed by subjects: Change from 47.0 (26.6) 6.7 (21.9) 63.6 (19.1) 2.6 (17.0) 67.0 (20.3) 2.0 (16.7) 49.3 (22.3) 3.8 (20.9) 57.8 (23.2) 6.0 (17.7) 49.3 (29.4) 9.0 (25.0) 62.3 (26.0) 6.6 (23.6) 58.8 (18.5) 4.9 (14.2) 46.3 (28.1) 11.9 (24.3) 64.8 (20.4) -2.3 (16.4) 66.9 (18.8) -2.7 (16.6) 49.9 (20.5) -0.9 (17.8) 59.7 (24.5) 2.3 (18.2) 53.6 (30.1) 5.5 (27.3) 61.4 (26.6) 6.4 (22.9) 59.4 (18.2) 2.3 (12.7) 6
7 Change, Week 8 (LOCF) N= (3.9) (3.9) (3.5) (3.2) (3.5) (2.9) NDDI-E completed by family members/friends: Change from N= Change, Week 8 (LOCF) ESS: Change from Change, Week 8 (LOCF) AEP: Change from Change, Week 8 (LOCF) CGI Week 8 Very much improved Much improved Minimally improved No change Minimally worse Much worse Week 20 Very much improved Much improved Minimally improved No change Minimally worse Much worse (4.3) -1.5 (3.1) -2.0 (3.2) (3.8) -0.3 (3.6) -0.1 (4.1) N= (4.9) (4.5) (3.7) (4.2) (4.6) (4.2) N= 40.8 (11.4) 40.8 (10.7) -2.0 (8.7) -1.6 (7.1) -2.2 (8.8) -1.9 (7.6) N= n n (%) n n (%) (18) 17 (17) 37 (36) 29 (29) 22 (22) 29 (29) 19 (19) 20 (20) 6 (6) 6 (6) (44) 29 (33) 10 (11) 9 (10) 1 (1) 0 (0) Median % Decrease from in Seizure Frequency N= Escalation Maintenance Entire Treatment Period (35) 28 (31) 17 (19) 9 (10) 1 (1) 3 (3) n Median n Median Safety Results: An on-therapy adverse event was defined as an adverse event with onset on or after the start date of study medication but not later than one day after the last date of study medication. An on therapy serious adverse event was defined as a serious adverse event with onset on or after the start date of study medication and up to 30 days after the last dose of medication. Subjects with any Adverse Events, n(%) 108 (82) 115 (85) Most Frequent Adverse Events On-Therapy 7
8 Adverse Events Reported in >5% of Patients in Either Treatment Group N= n (%) n (%) Headache 42 (32) 34 (25) Dizziness 17 (13) 21 (15) Nausea 14 (11) 13 (10) Fatigue 10 (8) 15 (11) Somnolence 7 (5) 16 (12) Nasopharyngitis 8 (6) 13 (10) Irritability 8 (6) 13 (10) Rash 8 (6) 9 (7) Pharyngolaryngeal pain 11 (8) 4 (3) Vomiting 11 (8) 4 (3) Insomnia 8 (6) 6 (4) Depression 4 (3) 8 (6) Sinusitis 3 (2) 8 (6) Toothache 3 (2) 8 (6) Serious Adverse Events - On-Therapy Subjects with non-fatal serious adverse events, n (%) [drug-related] 3 (2) [0] 9 (7) [0] Dehydration 1 (<1) [0] 2 (1) [0] Failure to thrive 0 (0) [0] 1 (<1) [0] Congestive cardiac failure 1 (<1) [0] 1 (<1) [0] Myocardial infarction 0 (0) [0] 1 (<1) [0] Breast cancer 0 (0) [0] 1 (<1) [0] Malignant lung neoplasm 1 (<1) [0] 0 (0) [0] Malignant neoplasm 0 (0) [0] 1 (<1) [0] Balance disorder 0 (0) [0] 1 (<1) [0] Convulsion 0 (0) [0] 1 (<1) [0] Abdominal pain 1 (<1) [0] 0 (0) [0] Nausea 1 (<1) [0] 0 (0) [0] Vomiting 1 (<1) [0] 0 (0) [0] Pneumonia 0 (0) [0] 1 (<1) [0] Uncontrolled diabetes mellitus 0 (0) [0] 1 (<1) [0] Confusional state 1 (<1) [0] 0 (0) [0] Dyspnea 1 (<1) [0] 0 (0) [0] Subjects with fatal serious adverse events, n (%) [drug-related] 1 (<1) [0] 0 (0) [0] Injury- Asphyxiation 1 (<1) [0] 0 (0) [0] Conclusion: Subjects receiving lamotrigine had a statistically significant improvement relative to levetiracetam as measured by the Anger-Hostility subscale score of the Profile of Mood States (POMS). In the lamotrigine group 108 subjects reported adverse events with the most frequently reported being headache and dizziness. In the levetiracetam group 115 subjects reported adverse events with the most frequently reported being headache and dizziness. Three subjects reported serious adverse events in the lamotrigine group and one subject experienced a fatal serious adverse event (reported by investigator to not be drug-related). Nine subjects reported serious adverse events in the levetiracetam group, none was fatal. 8
9 Publications: No Publication Date Updated: 08-May
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationStudy No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationPFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium
PFIZER INC These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBR
CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate
More informationSearch for studies: ClinicalTrials.gov Identifier: NCT
ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study F1J-MC-HMDV
CT Registry ID# 7108 Page 1 Summary ID# 7108 Clinical Study Summary: Study F1J-MC-HMDV Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMEDICATION GUIDE. The risk of getting a serious skin rash is higher if you:
MEDICATION GUIDE Lamotrigine (lam-oh-try-jeen) Tablets USP Rx only What is the most important information I should know about lamotrigine tablets? 1. Lamotrigine tablets may cause a serious skin rash that
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More information